The asco Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene and Aromatase Inhibition56 concluded that “placebo controls are appropriate for breast cancer risk reduction trials since no intervention has been demonstrated to favorably impact net health or survival.” Although the map.3 trial is not expected to demonstrate an impact on survival, the results may well indicate a more favourable therapeutic ratio for exemestane than for tamoxifen or raloxifene. The gene discussed is CYP19A1; the disease is breast cancer.